AG
SCLN

Algert Global’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Algert Global’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,537
Closed -$133K – 403
2017
Q1 		$133K Sell
13,537
-6,783
-33% -$67.7K 0.04% 305
2016
Q4 		$219K Buy
20,320
+6,054
+42% +$60.5K 0.06% 289
2016
Q3 		$146K Buy
+14,266
New +$155K 0.04% 346
2016
Q2 		– Sell
-32,873
Closed -$362K – 436
2016
Q1 		$362K Sell
32,873
-94,369
-74% -$839K 0.14% 254
2015
Q4 		$1.17M Buy
+127,242
New +$1.07M 0.55% 53

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Algert Global's SCLN Position: Q2 2017 in Review

Algert Global sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2017, closing a stake of 13,537 shares — an estimated $133K sold.

Algert Global first reported a position in SCLN in Q4 2015 and held it in 5 quarters. The position peaked at $1.17M in Q4 2015. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Algert Global reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Algert Global sold 13,537 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $133K.
  • Algert Global first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 5 quarters.
  • Algert Global's Sciclone Pharmaceuticals Inc position peaked at $1.17M in Q4 2015.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Algert Global's 13F filing for Q2 2017, filed 1 Aug 2017.